Clinical Trial Update: Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating mipomersen (ISIS-301012) as add-on therapy in patients with heterozygous familial hypercholesterolemia and coronary artery disease; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Familial Hypercholesterolemia

Drugs mentioned

• Mipomersen (ISIS-301012) (mipomersen)

Snippet

Sponsor: Kastle Therapeutics, LLC | Conditions: Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-03-21